Lavallée. Pathophysiological plasma ET-1 levels antagonize ␤-adrenergic dilation of coronary resistance vessels in conscious dogs. Am J Physiol Heart Circ Physiol 287: H1476 -H1483, 2004. First published June 17, 2004 10.1152/ajpheart.00297.2004.-On the basis of in vitro experiments showing that endothelin (ET)-1 interferes with smooth muscle ATP-sensitive K ϩ (KATP) channel opening, which is pivotal in ␤-adrenergic coronary dilation, we hypothesized that pathophysiological plasma ET-1 levels impair ␤-adrenergic dilation of resistance coronary vessels. In conscious instrumented dogs, graded intravenous doses of dobutamine caused the expected inotropic responses. As myocardial O2 consumption (MV O2) increased, the disproportionate rise in coronary sinus (CS) PO2 indicates that increases in coronary blood flow (CBF) exceeded metabolic requirements, consistent with ␤-adrenergic dilation. ET-1 intravenous infusions, to reach pathophysiological plasma levels, reduced slopes of the PO 2-MV O2 and CBF-MV O2 relations. In contrast, the first derivative of left ventricular pressure over time responses to dobutamine were not impaired during ET-1 delivery. Clazosentan, an ET A receptor blocker, prevented reduction of the slope of PO2-MV O2 and CBF-MV O2 relations. After ganglionic blockade to exclude reflex influences, ET-1 still reduced slopes of PO 2-MV O2 and CBF-MV O2 relations. To assess effects of ET-1 on endothelium-dependent and -independent coronary vascular responses, intracoronary ACh and nitroglycerin were given to directly target coronary vessels. CBF responses to ACh and nitroglycerin were maintained during ET-1 delivery. In contrast, responses to intracoronary K ATP channel-dependent dilators adenosine and lemakalim were impaired by ET-1. In conclusion, pathophysiological levels of ET-1 impaired ␤-adrenergic dilation of resistance coronary vessels through an ET A receptor-dependent process. In contrast, left ventricular inotropic responses to dobutamine were not impaired during ET-1 delivery. Our data suggest that ET-1 may interfere with smooth muscle K ATP channels to impair ␤-adrenergic coronary dilation. endothelin-1; coronary blood flow; dobutamine; ATP-dependent potassium channels; myocardial oxygen consumption PLASMA ENDOTHELIN (ET)-1 levels are elevated in human heart failure (1, 6, 13, 20, 24) and pulmonary hypertension (33). The pulmonary circulation acts as the primary source of circulating ET-1 (5, 24). Even if local ET-1 activity is increased in failing hearts (2), circulating ET-1 is still being extracted by the heart, which acts as a consumer, rather than a producer, of circulating ET-1 (5, 24). In humans, increases in circulating ET-1 levels within the pathophysiological range led to decreases in coronary sinus (CS) blood flow and venous blood O 2 saturation, consistent with coronary constriction (19). In normal conscious pigs (14, 15) and dogs (26), blockade of ET-1 receptors led to increases in coronary venous blood O 2 saturation. Thus ET-1 activity may reach the threshold for altering myocardial O 2 supply-demand balance in normal and pathophysiological states.
increases in coronary venous blood O 2 saturation. Thus ET-1 activity may reach the threshold for altering myocardial O 2 supply-demand balance in normal and pathophysiological states.
In the setting of heart failure, the neurohormonal response involves concomitant increases in ␤-adrenergic receptor activation and circulating ET-1 levels. The fact that, in vitro, ET-1 inhibits isoproterenol-stimulated cAMP accumulation in cardiomyocytes (10, 30) and pericardial smooth muscle cells (34) raises the possibility of a cross talk between ␤-adrenergic and ET-1 receptors, ET A receptors in particular. In support of that possibility, ET-1 has been shown in isolated vessels to blunt the opening of ATP-sensitive K ϩ (K ATP ) channels (18) , which is pivotal in ␤-adrenergic dilation of resistance coronary vessels (16) . Given that ␤-adrenergic receptor activation acts as a feedforward mechanism to cause coronary dilation in the face of heightened sympathetic activity (7), a blunted ␤-adrenergic coronary dilation caused by ET-1 would be expected to unfavorably alter the match between myocardial O 2 supply and demand.
METHODS

Instrumentation.
After general anesthesia with pentobarbital sodium (30 mg/kg iv) and under sterile conditions, 19 mongrel dogs (30 Ϯ 2 kg) underwent a left thoracotomy at the fifth intercostal space under artificial ventilation. The pericardium was widely incised parallel to the phrenic nerve. A Tygon (Norton Plastics and Synthetic Division) catheter was implanted in the thoracic aorta to measure arterial pressure via an external transducer (model 800, Bentley Trantec). Mean arterial pressure (MAP) was obtained with an active filter with a time constant of 2 s. Through an apical stab wound, a solid-state pressure transducer (model P6.5, Konigsberg Instruments) was inserted in the left ventricular (LV) cavity to record LV pressure (LVP) and its first derivative over time (LV dP/dt). A catheter was also implanted in the LV to cross calibrate the miniature pressure gauge and to eliminate any drift of the instrument through repeated calibrations. Additional catheters were implanted in the right atrium (RA) and in the proximal pulmonary artery (PA). A cardiotachometer (model 9857, Sensor Medics) triggered by LVP was used to monitor heart rate (HR). An ultrasonic Doppler blood flow transducer was placed around the circumflex coronary artery, 1-2 cm from the bifurcation of the left main coronary artery. Coronary blood flow (CBF) was monitored using a 10-MHz pulsed Doppler flowmeter. Mean CBF was obtained with an active filter with a time constant of 2 s. A Silastic (Dow Corning) catheter was implanted in the CS. The tip of the catheter was Ն1 cm from the CS ostium. The position of the CS catheter was confirmed at necropsy. The pericardium was loosely closed, the chest was closed in layers, and the catheters and wires were exteriorized on the back of the animals. Analgesia was provided postoperatively with buprenorphine (0.3 mg im; Reckitt and Colman Pharmaceuticals). Prophylactic procaine penicillin G (300,000 units im) and benzathine penicillin G (300,000 units im) were administered for 10 days after the surgery.
Hemodynamic variables were recorded on a VHS tape via a PCM recording adaptor (model 4000A, Vetter) and monitored on a direct ink-writing strip chart recorder (model 2800s, Gould).
Protocols. Experiments were initiated 2-4 wk after surgery in conscious healthy dogs lying on a table of a dimly illuminated laboratory. While the dogs were resting quietly, hemodynamic variables were continuously monitored until a stable baseline was reached. At that time, blood samples (1 ml) were simultaneously withdrawn in lightly heparinized syringes from the aortic and CS catheters to measure hemoglobin (Hb) concentration, PO2, and Hb O2 saturation. An additional arterial blood sample (3 ml) was transferred to chilled tubes containing EDTA and placed on ice for later ET-1 determinations. These samples were centrifuged at 3,000 rpm and 3°C, and the plasma was collected and stored at Ϫ70°C until the day of the assay. ET-1 was measured with a sensitive and specific ELISA (Biomedica). Hb concentration, Hb O2 saturation, and PO2 were measured immediately after blood collection. A CO-oximeter (model OSM-2, Radiometer) was used to measure Hb concentration and Hb O2 saturation. PO2 was measured on a Stat Profile pHOx analyzer (Nova Biomedical).
Dobutamine hydrochloride (Sabex), a ␤-adrenergic agonist, was administered through the PA catheter at 2.5, 5.0, and 7.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 until a steady state was reached (4 -6 min); CS and aortic blood samples were then collected for blood gas analysis. The same protocol was repeated during ET-1 (2.5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ; American Peptide) delivery (n ϭ 7) through the RA catheter. In all experiments, ET-1 was delivered for 30 min before the beginning of dobutamine infusions and maintained thereafter. Arterial blood samples for ET-1 measurements were obtained 30 min after the beginning of ET-1 delivery and at the completion of dobutamine infusions. This ensured that steady-state plasma ET-1 levels were reached during exogenous ET-1 delivery. On a separate day, dobutamine infusions were made 30 min after the beginning of a continuous RA infusion of ET-1 (4.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 , n ϭ 8). In additional experiments (n ϭ 8), dobutamine was infused through the PA during delivery of ET-1 (4.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) through the RA after administration of clazosentan (Actelion), an ETA receptor blocker (21) . Clazosentan was delivered through a peripheral vein as a priming dose of 50.0 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for 10 min followed by 5.0 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for the duration of the experiments. In additional experiments (n ϭ 7), dobutamine was administered before and 30 min after the beginning of a continuous clazosentan infusion.
In additional experiments (n ϭ 6), dobutamine was administered before and 30 min after the beginning of a continuous RA infusion of ET-1 (4.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) after ganglionic blockade with RA infusions of hexamethonium bromide (35.0 mg/kg; Sigma) and methyl atropine (0.1 mg/kg; Sigma). In additional dogs (n ϭ 6) instrumented as described above (without the CS catheter), a Silastic catheter was implanted in the lumen of the proximal circumflex coronary artery, upstream from the Doppler flow probe. The portion of the catheter within the coronary vessel had an external diameter of 0.6 mm. Intracoronary boluses of acetylcholine chloride (ACh, 1.0 and 3.0 ng/kg; Sigma) and nitroglycerin (NTG, 100.0 ng/kg; Parke-Davis) were administered before and 30 min after the beginning of a continuous RA infusion of ET-1 (4.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ). . Coronary vascular resistance (CVR) is the ratio of MAP to CBF. A one-way analysis of variance for repeated measurements was used to compare variables with baseline. A two-way analysis of variance was used for simultaneous overall comparisons of dobutamine, ACh, adenosine, or lemakalim responses before and after treatment. Post hoc comparisons were made with the Newman-Keuls test to isolate specific contrasts. Slopes of relations between MV O2 and CS PO2 or CBF were established for each animal and compared with an analysis of variance or a paired t-test. Paired t-tests were used when NTG-induced CBF responses before and after ET-1 were compared. Statistical significance was reached when P Ͻ 0.05 in all cases. All experimental procedures were performed in accordance with institutional guidelines.
RESULTS
Dobutamine with or without ET-1 delivery.
Under control conditions, dobutamine increased LVP, LV dP/dt, MAP, and HR (Tables 1 and 2 ). As a consequence of changes in the determinants of cardiac metabolic demand, cardiac MV O 2 and CBF increased. The rise in CS PO 2 concomitant with the increase in MV O 2 indicates that CBF was in excess of cardiac metabolic requirements during dobutamine delivery. Therefore, dobutamine had significant dilator effects in addition to its metabolic activity. The hemodynamic effects of dobutamine and the slope of the relations between CS PO 2 or CBF and MV O 2 did not significantly differ before the various interventions, i.e., before ET-1 (2.5 and 4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ), clazosentan, or ET-1 ϩ clazosentan. Table 1 reports the hemodynamic effects of graded doses of dobutamine before and during ET-1 (2.5 ng⅐kg Ϫ1 ⅐min Ϫ1 ). ET-1 increased baseline MAP and CVR and decreased LV dP/dt and HR. Except for increases in CS PO 2 caused by dobutamine that were smaller during ET-1 (2.5 ng⅐kg Ϫ1 ⅐min Ϫ1 ) than before ET-1, other hemodynamic responses did not differ before and during ET-1. The slopes of the relations between CS PO 2 or CBF and MV O 2 were reduced during dobutamine ϩ ET-1; i.e., for any given increase in MV O 2 caused by dobutamine, PO 2 and CBF increased less during ET-1 than before ET-1 ( Fig. 1 ). Thus ET-1 impaired coronary dilator effects of dobutamine. Table 2 reports the hemodynamic effects of graded doses of dobutamine before and during ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ). ET-1 increased LVP, MAP, and CVR and decreased HR. Dobutamine-induced LV dP/dt responses were increased during ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ), whereas CS PO 2 responses were decreased. The slopes of the relations between CS PO 2 or CBF and MV O 2 were reduced during dobutamine ϩ ET-1 (Fig.  2) . Baseline arterial plasma ET-1 levels averaged 0.5 Ϯ 0.1 fmol/ml. ET-1 delivery (2.5 and 4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) increased (P Ͻ 0.01) plasma levels to 3.4 Ϯ 0.5 (n ϭ 7) and 7.2 Ϯ 1.1 (n ϭ 8) fmol/ml, respectively, after 30 min. A steady-state plasma ET-1 level was maintained thereafter (Fig. 3) . Data for ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) at the completion of the experiments were available in six dogs.
Dobutamine ϩ ET-1 delivery with or without blockade of ET A receptors.
Clazosentan ϩ ET-1 resulted in lower baseline LVP and MAP and higher HR than ET-1 alone. LV dP/dt responses to dobutamine were reduced and CS PO 2 responses were increased during ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) ϩ clazosentan compared with ET-1 alone. Other hemodynamic responses to dobutamine did not differ from those observed with ET-1 alone ( Table 2 ). The slopes of the relations between CS PO 2 or CBF and MV O 2 during dobutamine after ET-1 ϩ clazosentan did not significantly differ from those after dobutamine alone (Fig. 2) .
Blockade of ET A receptors alone. The slopes of the relations between CS PO 2 or CBF and MV O 2 during dobutamine delivery did not statistically differ before and after clazosentan. Clazosentan increased (P Ͻ 0.01) plasma ET-1 levels from 0.6 Ϯ 0.1 to 1.8 Ϯ 0.2 fmol/ml.
Ganglionic blockade ϩ dobutamine with or without ET-1. After ganglionic blockade, dobutamine caused greater (P Ͻ 0.05) dose-dependent increases in MV O 2 with ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) than without ET-1. The slopes of the relations between CS PO 2 or CBF and MV O 2 during dobutamine were reduced (P Ͻ 0.05) after ET-1, consistent with impaired dilator effects (Fig. 4) . ET-1 did not significantly alter baseline LV dP/dt (from 2,501 Ϯ 135 to 2,308 Ϯ 49 mmHg/s). Before ET-1, dobutamine-induced LV dP/dt increases averaged 1,261 Ϯ 170, 2,566 Ϯ 314, and 3,653 Ϯ 365 mmHg/s at 2.5, 5.0, and 7.5 g⅐kg Ϫ1 ⅐min
Ϫ1
, respectively. During ET-1, LV dP/dt responses to 2.5, 5.0, and 7.5 g ⅐kg Ϫ1 ⅐min Ϫ1 dobutamine averaged 1,419 Ϯ 180, 3,097 Ϯ 355, and 4,453 Ϯ 395 mmHg/s, respectively, with greater (P Ͻ 0.01) responses than before ET-1 for the two higher doses of dobutamine.
Nitric oxide-dependent responses with and without ET-1. Endothelium-dependent and -independent responses to intracoronary boluses of ACh and NTG, respectively, were compared before and during ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) in six dogs. Baseline CBF was not significantly altered by ET-1. ET-1 did not interfere with peak, volume, or duration of CBF responses triggered by intracoronary ACh and NTG (Fig. 5 ). ACh and NTG had no other hemodynamic effects.
Adenosine with or without ET-1. Intracoronary adenosine was delivered before and during ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) in five dogs. The effects of adenosine were limited to changes in CBF. Baseline CBF was not significantly altered by ET-1. Adenosine-induced increases in CBF were substantially reduced by ET-1 (Fig. 6) .
Lemakalim with or without ET-1. Intracoronary boluses of lemakalim were delivered before and during ET-1 (4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) in five additional dogs. The effects of lemakalim were limited to changes in CBF. Baseline CBF was not significantly altered by ET-1. ET-1 reduced peak, volume, and duration of CBF responses triggered by intracoronary lemakalim (Fig. 7) .
DISCUSSION
The main finding of the present study is that plasma ET-1 within the pathophysiological range impairs ␤-adrenergic dilation of resistance coronary vessels caused by dobutamine in conscious dogs. In contrast, ET-1 failed to impair dobutamineinduced LV positive inotropic responses. Blockade of ET A receptors prevented the inhibitory action of ET-1 on ␤-adrenergic coronary dilation. Our data after ganglionic blockade indicate that reflex mechanisms were not involved in the cross talk between ET-1 and ␤-adrenergic receptors. The lack of inhibitory effects of ET-1 on ACh-and NTG-induced dilation of resistance coronary vessels excludes nitric oxide (NO) as a key intermediate in the ␤-adrenergic receptor-ET-1 interaction. Our data showing that ET-1 also antagonized responses to the K ATP channel-dependent dilators adenosine and lemakalim are consistent with the involvement of these channels in the ET-1-␤-adrenergic receptor cross talk in the coronary microcirculation.
In the present study, our selection of doses of ET-1 for systemic delivery was guided by earlier studies showing that ET-1 at 2.5 ng⅐ kg Ϫ1 ⅐min Ϫ1 reaches the pathophysiological range (4, 11) . Our measurements of plasma ET-1 are consistent with values reported in human (1, 6, 13, 20, 24) and animal heart failure (3, 22, 25) . Our larger dose of ET-1 (4.0 ng⅐ kg Ϫ1 ⅐min Ϫ1 ) is close to the upper limit of the pathophysiological range of ET-1 plasma levels reported earlier. Thus circulating ET-1 levels within the pathophysiological range reach the threshold for impairing ␤-adrenergic dilation of resistance coronary vessels.
Our approach involves analyses of relations between CS PO 2 or CBF and MV O 2 to assess the balance between myocardial O 2 supply and demand. As expected, graded doses of dobutamine alone increased MV O 2 secondary to higher cardiac metabolic demand. As MV O 2 increased, the rise in CBF was accompanied by elevations of CS blood PO 2 , indicative of a shift in the O 2 supply-demand balance. Therefore, the increases in CBF triggered by ␤-adrenergic receptor activation exceeded cardiac metabolic demand, consistent with a direct coronary dilator process. The positive slope of the relation between CS PO 2 and MV O 2 reflects the magnitude of dilator responses. A perfect match between CBF and cardiac metabolic demand would be translated into a slope of the PO 2 -MV O 2 relation close to zero.
In the present study, elevations of circulating ET-1 levels decreased the slope of the relation between CS PO 2 or CBF and MV O 2 . As MV O 2 increased during dobutamine administration, CS PO 2 and CBF rose disproportionately less after ET-1 (2.5 or 4.0 ng⅐kg Ϫ1 ⅐min Ϫ1 iv) than before ET-1. Thus dobutamine- induced coronary dilation was reduced by elevations of circulating levels of ET-1. If ET-1 completely prevented coronary dilation to dobutamine, the slope of the PO 2 -MV O 2 relation should become negative, as demonstrated earlier in dogs (17) , when CBF is solely driven by cardiac metabolic demand. Consequently, a residual dilator effect of dobutamine remained during ET-1 delivery.
In the present study, we have ensured that plasma ET-1 levels reached a steady state throughout the dobutamine infusions. This makes it unlikely that a growing vasoconstrictor influence of ET-1 accounted for the impaired ␤-adrenergic coronary dilation reflected by the reduction in the slopes of CS PO 2 and CBF vs. MV O 2 relations. Given that ET-1 lacked significant effects on baseline CBF, CS PO 2 , and MV O 2 in the present study, the reduction of ␤-adrenergic coronary dilation cannot be causally related to a competition with a vasoconstrictor effect of ET-1. The maintained ACh-and NTG-induced dilator responses after ET-1 are consistent with this conclusion.
On the basis of our previous studies showing that blockade of NO formation impairs ␤-adrenergic dilation of resistance coronary vessels (16), we were led to hypothesize that ET-1 may interfere with NO-dependent dilation, thereby limiting ␤-adrenergic dilation. Our data with intracoronary administration of ACh and NTG to avoid the confounding influence of changes in hemodynamic variables argue against that possibility, because responses to both agonists were maintained in the face of elevated ET-1 plasma levels. These data also imply that the inhibitory effect of ET-1 on coronary dilation is selectively displayed against ␤-adrenergic effects and does not extend to other vasodilators, such as ACh and NTG. This rules out the possibility that ET-1 acted as a nonspecific inhibitor of coronary dilation.
Earlier, we demonstrated that opening of K ATP channels plays a pivotal role in ␤-adrenergic dilation of resistance coronary vessels (16) . Conceivably, ET-1 may interfere with K ATP channels to impair ␤-adrenergic coronary dilation. Consistent with this hypothesis, patch-clamp experiments on isolated vascular smooth muscle cells indicate that ET-1 blocks K ATP channels (18) . Furthermore, cromakalim, a K ATP channel opener, prevented ET-1-induced constriction of dorsal hand veins in humans (8) . If ET-1 interferes with the opening of K ATP channels, adenosine-induced dilation, which primarily involves the opening of K ATP channels on coronary microvessels (9), should also be impaired. As predicted, ET-1 antagonized CBF responses to intracoronary adenosine to specifically target coronary vessels. To directly demonstrate an inhibitory effect of ET-1 on K ATP -dependent responses, the effects of intracoronary lemakalim, a K ATP channel opener, were assessed before and during ET-1 delivery. As expected, ET-1 antagonized lemakalim-induced CBF responses. Taken together, the above findings are consistent with the possibility of an inhibitory effect of ET-1 on ␤-adrenergic dilation of resistance coronary vessels through a K ATP channel-dependent process.
In contrast to coronary responses, LV inotropic effects of dobutamine were maintained and even increased during ET-1 delivery. The rise in MAP caused by ET-1 may have influenced LV inotropic responses to dobutamine by increasing baroreflex influences. To assess that possibility, experiments were conducted after ganglionic blockade. In that situation, dobutamine-induced LV dP/dt increases were augmented by ET-1, whereas coronary dilator responses were blunted. The present data are at variance with reports on isolated cardiomyocytes, where exposure to ET-1 prevented isoproterenol-induced cAMP increases (10, 30) and the opening of L-type Ca 2ϩ channels (27, 32) , which should impair inotropic responses. Presumably, species differences account for the discrepancy of ET-1 effects on ␤-adrenergic responses in cardiomyocytes. In myocardial sarcolemmal preparations of ventricular human tissue, ET-1 failed to alter stimulated cAMP production caused by isoproterenol and forskolin (31) . ET-1 has been reported to blunt cAMP accumulation in human pericardial smooth muscle cells (34) , a finding consistent with our data on vascular responses.
A previous study has examined the effects of elevations of circulating ET-1 levels to the pathophysiological range under baseline conditions in anesthetized dogs (11) . A rise in ET-1 created by exogenous ET-1 (2.5 ng⅐kg Ϫ1 ⅐min
Ϫ1
) failed to alter baseline CBF in anesthetized dogs. Although the balance between O 2 supply and demand was not specifically examined in that study, the present data agree with the conclusion that ET-1 has little influence on baseline CBF. NO and prostacyclin production may counteract ET-1-dependent coronary constriction (12, 29) , as suggested earlier.
In the present study, clazosentan failed to alter baseline CS PO 2 , consistent with limited ET-dependent effects under baseline conditions. In contrast, CS Hb O 2 saturation has been reported to increase after ET A or ET A /ET B receptor blockade in earlier studies (15, 26) , consistent with significant baseline ET-1-dependent constrictor effects. Our present data also indicate a rise in percent Hb O 2 saturation levels (from 18.9 Ϯ 3.6 to 20.7 Ϯ 4.3%, P Ͻ 0.05) after clazosentan. This emphasizes the possibility of a discrepancy arising from the use of CS Hb O 2 saturation levels as a surrogate for CS PO 2 .
In the present study, ET receptors accounting for the ET-1-␤-adrenergic cross talk were of the ET A subtype. ET A receptor blockade with clazosentan prevented the reduction in slope of the CS PO 2 -MV O 2 relation caused by ET-1 given during dobutamine. We previously demonstrated in canine isolated large epicardial coronary arteries that clazosentan (Ro 61-1790) antagonized ET-1-induced contraction through the blockade of ET A receptors (28) . In our conscious dogs, systemic clazosentan caused a modest but significant increase in baseline circulating ET-1 levels, presumably as a result of displacement of native ET-1 from its binding sites. It is unlikely that a substantial blockade of ET-1 clearance through ET B receptor blockade was involved, given that acute blockade of ET A /ET B receptors in dogs caused disproportionately greater (10-to 20-fold increase from baseline) increases in circulating ET-1 levels than those observed in the present study (23, 26) . In the aggregate, ET A receptors were pivotal in the inhibitory action of ET-1 on ␤-adrenergic dilation of resistance coronary vessels.
In conclusion, pathophysiological levels of ET-1 substantially impair ␤-adrenergic dilation of resistance coronary vessels through an ET A receptor-dependent process. In contrast, endothelium-dependent and -independent coronary responses to ACh and NTG were maintained during ET-1 delivery. On the basis of the inhibitory effect of ET-1 on adenosine-and lemakalim-induced dilation, blockade of K ATP channels is most likely the mechanism by which ET-1 impairs ␤-adrenergic coronary dilation. As opposed to the inhibitory effects of ET-1 on vascular ␤-adrenergic responses, LV inotropic responses to dobutamine were not impaired by ET-1. On a speculative basis, ET-1 receptor blockade may serve as significant adjunct to dobutamine to improve the match between myocardial O 2 supply and demand in patients requiring inotropic support. 
